...
esla-img

Estrella Immunopharma Inc., Common Stock

ESLA

NAQ

$1.22

+$0.02

(1.67%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$43.41M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
58.13K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.24
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.63 L
$3.23 H
$1.22

About Estrella Immunopharma Inc., Common Stock

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameESLASectorS&P500
1-Week Return7.49%-1.57%0.94%
1-Month Return43.53%-1.86%5.38%
3-Month Return15.09%-6.07%10.61%
6-Month Return31.18%-0.47%13.65%
1-Year Return-4.69%10%33.13%
3-Year Return-87.71%10.67%32.44%
5-Year Return-87.49%45.46%94.89%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses733.69K1.69M1.57M7.31M[{"date":"2020-12-31","value":10.04,"profit":true},{"date":"2021-12-31","value":23.06,"profit":true},{"date":"2022-12-31","value":21.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(733.69K)(1.69M)(1.57M)(7.31M)[{"date":"2020-12-31","value":-73369300,"profit":false},{"date":"2021-12-31","value":-168534700,"profit":false},{"date":"2022-12-31","value":-156953000,"profit":false},{"date":"2023-12-31","value":-731009800,"profit":false}]
Total Non-Operating Income/Expense----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(733.69K)(1.69M)(915.46K)(7.31M)[{"date":"2020-12-31","value":-73369300,"profit":false},{"date":"2021-12-31","value":-168534700,"profit":false},{"date":"2022-12-31","value":-91545600,"profit":false},{"date":"2023-12-31","value":-731009800,"profit":false}]
Income Taxes(206.30K)(235.14K)80.65K-[{"date":"2020-12-31","value":-255.8,"profit":false},{"date":"2021-12-31","value":-291.56,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(733.69K)(1.69M)(6.88M)(7.31M)[{"date":"2020-12-31","value":-73369300,"profit":false},{"date":"2021-12-31","value":-168534700,"profit":false},{"date":"2022-12-31","value":-688422700,"profit":false},{"date":"2023-12-31","value":-731172300,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(733.69K)(1.69M)(996.10K)(7.31M)[{"date":"2020-12-31","value":-73369300,"profit":false},{"date":"2021-12-31","value":-168534700,"profit":false},{"date":"2022-12-31","value":-99610400,"profit":false},{"date":"2023-12-31","value":-731172300,"profit":false}]
EPS (Diluted)-(0.14)(0.25)(1.87)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-14,"profit":false},{"date":"2022-12-31","value":-25,"profit":false},{"date":"2023-12-31","value":-186.57,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ESLA
Cash Ratio 0.60
Current Ratio 0.75
Quick Ratio 0.84

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ESLA
ROA (LTM) -122.12%
ROE (LTM) -278.12%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ESLA
Debt Ratio Lower is generally better. Negative is bad. 0.80
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.20

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ESLA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 58.17
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Estrella Immunopharma Inc. share price today?

Estrella Immunopharma Inc. (ESLA) share price today is $1.22

Can Indians buy Estrella Immunopharma Inc. shares?

Yes, Indians can buy shares of Estrella Immunopharma Inc. (ESLA) on Vested. To buy Estrella Immunopharma Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ESLA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Estrella Immunopharma Inc. be purchased?

Yes, you can purchase fractional shares of Estrella Immunopharma Inc. (ESLA) via the Vested app. You can start investing in Estrella Immunopharma Inc. (ESLA) with a minimum investment of $1.

How to invest in Estrella Immunopharma Inc. shares from India?

You can invest in shares of Estrella Immunopharma Inc. (ESLA) via Vested in three simple steps:

  • Click on Sign Up or Invest in ESLA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Estrella Immunopharma Inc. shares
What is Estrella Immunopharma Inc. 52-week high and low stock price?

The 52-week high price of Estrella Immunopharma Inc. (ESLA) is $3.23. The 52-week low price of Estrella Immunopharma Inc. (ESLA) is $0.63.

What is Estrella Immunopharma Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Estrella Immunopharma Inc. (ESLA) is

What is Estrella Immunopharma Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Estrella Immunopharma Inc. (ESLA) is 58.17

What is Estrella Immunopharma Inc. dividend yield?

The dividend yield of Estrella Immunopharma Inc. (ESLA) is 0.00%

What is the Market Cap of Estrella Immunopharma Inc.?

The market capitalization of Estrella Immunopharma Inc. (ESLA) is $43.41M

What is Estrella Immunopharma Inc.’s stock symbol?

The stock symbol (or ticker) of Estrella Immunopharma Inc. is ESLA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top